Trial Profile
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145/LN-145-S1) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs LN 145 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 31 Aug 2022 Status changed from active, no longer recruiting to completed.
- 11 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2020 Planned number of patients changed from 47 to 55.